Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any congenital disorder of glycosylation in which the cause of the disease is a mutation in A4GALT.
Biomarker and diagnostic research for A4GALT-congenital disorder of glycosylation has been reported in the published literature.
No clinical trials have been registered for A4GALT-congenital disorder of glycosylation.
249 publications have been identified in PubMed for A4GALT-congenital disorder of glycosylation. Kisho has analyzed 30 by research type. Research spans Review / Meta-Analysis (50%), Basic Science / Preclinical (30%), and Epidemiology / Natural History (10%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 15 | 50% |
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 4:39 PM UTC
Common questions about A4GALT-congenital disorder of glycosylation
Laboratory research |
9 |
30% |
Disease patterns and progression | 3 | 10% |
Other research | 1 | 3% |
Testing and diagnosis research | 1 | 3% |
Patient case studies | 1 | 3% |
Yi L (2026). [PMID: 41264770](https://pubmed.ncbi.nlm.nih.gov/41264770/). *Protein Cell*. [Review / Meta-Analysis]
Pinho SS (2025). [PMID: 40398097](https://pubmed.ncbi.nlm.nih.gov/40398097/). *Semin Immunol*. [Other]
Edmondson AC (2025). [PMID: 40737785](https://pubmed.ncbi.nlm.nih.gov/40737785/). *Mol Genet Metab*. [Epidemiology / Natural History]
Prakash S (2025). [PMID: 40153534](https://pubmed.ncbi.nlm.nih.gov/40153534/). *J Clin Invest*. [Basic Science / Preclinical]
Stentenbach M (2025). [PMID: 40480980](https://pubmed.ncbi.nlm.nih.gov/40480980/). *Nat Commun*. [Case Report / Case Series]
Li B (2025). [PMID: 40849276](https://pubmed.ncbi.nlm.nih.gov/40849276/). *Trends Pharmacol Sci*. [Review / Meta-Analysis]
Zhou Q (2025). [PMID: 40660266](https://pubmed.ncbi.nlm.nih.gov/40660266/). *Cardiovasc Diabetol*. [Review / Meta-Analysis]
Jáñez Pedrayes A (2025). [PMID: 40576648](https://pubmed.ncbi.nlm.nih.gov/40576648/). *Cell Mol Life Sci*. [Basic Science / Preclinical]
Du X (2025). [PMID: 39991767](https://pubmed.ncbi.nlm.nih.gov/39991767/). *Int J Med Sci*. [Review / Meta-Analysis]
Duarte HO (2025). [PMID: 40442468](https://pubmed.ncbi.nlm.nih.gov/40442468/). *Handb Exp Pharmacol*. [Review / Meta-Analysis]
AI-curated news mentioning A4GALT-congenital disorder of glycosylation
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.